Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Main subject
Language
Document Type
Year range
1.
ESMO Open ; 6(3): 100131, 2021 06.
Article in English | MEDLINE | ID: covidwho-1242977

ABSTRACT

BACKGROUND: European Society for Medical Oncology Women for Oncology (ESMO W4O) research has previously shown under-representation of female oncologists in leadership roles. As early reports suggested disproportionate effects of the COVID-19 pandemic on women, the ESMO W4O Committee initiated a study on the impact of the pandemic on the lives of female and male oncologists. METHODS: A questionnaire was sent to ESMO members and put on the ESMO website between 8 June 2020 and 2 July 2020. Questions focused on the working (hospital tasks, laboratory tasks, science) and home (household management, childcare, parent care, personal care) lives of oncologists during and after COVID-19-related lockdowns. RESULTS: Of 649 respondents, 541 completed the questionnaire. Of these, 58% reported that COVID-19 had affected their professional career, 83% of whom said this was in a negative way (85% of women versus 76% of men). Approximately 86% reported that COVID-19 had changed their personal life and 82% their family life. Women were again significantly more affected than men: personal life (89% versus 78%; P = 0.001); family life (84% versus 77%; P = 0.037). During lockdowns, women reported increased time spent on hospital and laboratory tasks compared with men (53% versus 46% and 33% versus 26%, respectively) and a significantly higher proportion of women than men spent less time on science (39% versus 25%) and personal care (58% versus 39%). After confinement, this trend remained for science (42% versus 23%) and personal care (55% versus 36%). CONCLUSIONS: The COVID-19 pandemic has adversely affected the professional and home lives of oncologists, especially women. Reduced research time for female oncologists may have long-lasting career consequences, especially for those at key stages in their career. The gender gap for promotion to leadership positions may widen further as a result of the pandemic.


Subject(s)
COVID-19 , Adult , Communicable Disease Control , Female , Humans , Male , Medical Oncology , Middle Aged , Oncologists , Pandemics , SARS-CoV-2 , Surveys and Questionnaires , Young Adult
2.
Annals of Oncology ; 31:S1005, 2020.
Article in English | EMBASE | ID: covidwho-804763

ABSTRACT

Background: CureCancer is a patient-centered/patient-driven digital tool integrated in the routine oncology practice. Patients self-create their medical profile, record their symptoms and communicate them to health care professionals (HCPs). We aimed to assess the tool’s feasibility and patients’ satisfaction. Methods: 14 Centers participated, starting from 02.2020. COVID-19 epidemic period was included. Patients signed consent to upload their data, report their symptoms and complete 2 questionnaires. Results following the completion of the 1st questionnaire are reported. Results: 78 patients were enrolled and 68 (87%) uploaded their data to date;60 of 68 (88%), 30 males and 30 females, median age 53 years, completed the 1st questionnaire. Thirty-seven (61.6%) were University graduates. Cancer types included breast cancer (21.6%), Head/Neck cancer, pancreatic cancer and other cancers. Ten patients reported “other”, 4 reported multiple cancers, 28 had metastatic disease and 45 active treatment. Registration and use of the platform was reported as “very to very much” easy by 52 (86.6%) and 50 (83.3%) patients, respectively. File uploading was “very to very much” easy for 33 (55%) patients;49 (81.6%) preferred the digital way and 50 (83.3%) will introduce it to others. Patients highlighted that CureCancer improved communication with HCPs, increased their sense of safety, facilitated treatment adherence and interventions at distance, particularly when outside the Cancer Center and during the COVID-19 pandemic, reduced the number of visits, time and out-of-pocket expenses. Benefits liked best were easy data access, improved communication and sense of safety. Conclusions: CureCancer use was feasible, increased communication with HCPs, patients’ sense of safety, treatment adherence and medical interventions at distancing, reduced visits and saved time and money. Continuing integration of CureCancer to embed PROs in routine cancer care is expected to improve treatment outcomes within or outside the Cancer Center and in pandemics and to reduce costs. Legal entity responsible for the study: Hellenic Society of Medical Oncology. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

SELECTION OF CITATIONS
SEARCH DETAIL